Core Insights - Propanc Biopharma's lead asset, PRP, is positioned as a novel therapeutic approach for treating and preventing metastatic cancer, particularly in aggressive solid tumors like pancreatic cancer, which has a low five-year survival rate of 13% compared to an overall cancer survival rate of 70% [1][2]. Company Overview - Propanc Biopharma, Inc. is focused on developing innovative treatments for chronic diseases, including cancer, by targeting cancer stem cells to prevent recurrence and metastasis [7]. Product Details - PRP is an investigational proenzyme therapy composed of trypsinogen and chymotrypsinogen in a 1:6 ratio, delivered intravenously. It aims to selectively target cancer stem cells, inhibit metastasis, disrupt the tumor microenvironment, reduce angiogenesis, and enhance the effectiveness of standard treatments with lower toxicity [3][6]. Market Potential - The global pancreatic cancer treatment market is valued at approximately $4.42 billion in 2026 and is projected to grow to $14.43 billion by 2034, reflecting a compound annual growth rate (CAGR) of around 16% due to increasing cases and demand for improved treatment options [5]. Clinical Development - Propanc is preparing for a Phase 1b First-In-Human trial in 2026, which will involve 30-40 patients with advanced solid tumors. The company has secured $100 million in funding, obtained new patents, and received FDA Orphan Drug status for pancreatic cancer [5]. Preclinical Data - Preclinical studies have shown that PRP can achieve over 85% tumor growth inhibition in pancreatic cancer models, reduce fibrosis and resistance markers, and has a favorable safety profile with no major side effects reported in limited prior human use [4].

Core Insights - Anixa Biosciences will host its 2026 Annual Meeting of Stockholders on March 10, 2026, in a virtual format, which will be open to all interested parties, including non-stockholders [1] - The meeting will feature a corporate update from Anixa's Chairman and CEO, Dr. Amit Kumar, highlighting recent clinical milestones in the oncology pipeline [1] Clinical Progress - The final Phase 1 data from the breast cancer vaccine program met primary endpoints, demonstrating favorable tolerability and immune responses in the majority of participants [1] - Encouraging survival observations were reported in the ongoing Phase 1 ovarian cancer CAR-T trial, along with regulatory approval for substantial dose escalation [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel) for ovarian cancer [1] - The company collaborates with Moffitt Cancer Center to develop a novel CAR-T technology, which utilizes the natural ligand of the FSHR receptor [1] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [1]

Core Insights - Anixa Biosciences has announced the final results of its Phase 1 clinical trial for a breast cancer vaccine, which will be presented at the 2025 San Antonio Breast Cancer Symposium [1][2][3] - The trial, funded by the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer [2][3] - The results are expected to inform discussions with the FDA and advance plans for Phase 2 development [1][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine technologies target "retired" proteins expressed in certain cancers, including breast and ovarian cancer, developed at Cleveland Clinic and exclusively licensed to Anixa [4] - Anixa's business model involves partnerships with leading research institutions to explore emerging technologies for further development and commercialization [4]

Core Insights - Anixa Biosciences, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1][2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] - The company utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to tumor cells [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - The vaccines are based on immunizing against "retired" proteins expressed in certain cancer forms, with Cleveland Clinic entitled to royalties and commercialization revenues from these technologies [2] - Anixa's business model involves partnerships with renowned research institutions at all development stages, allowing the company to explore emerging technologies for further development and commercialization [2]

Core Insights - Anixa Biosciences, Inc. is gaining media attention for its breast cancer vaccine, which has the potential to transform breast cancer treatment and prevention [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, targeting various cancers including lung, colon, and prostate [5] Vaccine Mechanism - The breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells by targeting the lactation protein α-lactalbumin, which is expressed in malignant breast cancer cells [2] - This vaccine aims to activate cytotoxic T cells to provide preemptive immune protection against emerging breast tumors [2] Media Coverage - The New York Post and Fox News have featured Anixa's breast cancer vaccine, highlighting its potential impact on breast cancer treatment [1][3]

Core Insights - Anixa Biosciences has made significant progress in its clinical and pre-clinical development programs in 2025, maintaining fiscal discipline while advancing its oncology treatment initiatives [1][5] Financial Performance - The company has maintained an average annual cash burn of approximately $5–6 million, which is significantly lower than typical for development-stage biotechnology companies [2] - In the most recent fiscal year, the cash burn was limited to $7 million while advancing two clinical trials [2] - Anixa ended the most recent quarter with over $17 million in cash and no debt, providing more than two years of operational runway [3] Capital Structure - Anixa has a clean capital structure with approximately 32 million common shares outstanding and no warrants [4] - Directors and senior management have consistently purchased stock on the open market, collectively investing millions of dollars, indicating strong belief in the company's long-term value [4] Clinical Programs - The CAR-T therapy program targeting recurrent, platinum-resistant ovarian cancer is progressing, with three dose-escalation cohorts completed in the Phase 1 trial [6][7] - Encouraging signs of efficacy have been observed, with one patient surviving two years post-treatment, significantly exceeding the typical four-month median survival for this population [7] - The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is nearing enrollment completion in its Phase 1 trial, with over 70% of patients showing protocol-defined immune responses [9][11] Future Milestones - Key milestones for the second half of 2025 include final Phase 1 data for the breast cancer vaccine, anticipated FDA interactions, and the initiation of the fourth cohort for the CAR-T ovarian cancer program [15][17] - The company is preparing to extend its vaccine platform to target prostate, lung, and colon cancers, addressing substantial unmet needs in these areas [13][14]

Core Insights - Anixa Biosciences, Inc. is set to present at the 2025 Cancer Advocacy Group of Louisiana NeauxCancer Conference, highlighting its advancements in cancer treatment and prevention [1][2] - The presentation will focus on Anixa's CAR-T therapy for solid tumors and novel cancer vaccine initiatives, showcasing the company's progress in clinical development and next-generation immunotherapies [2] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4] - Anixa's business model involves collaboration with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [4]